Akari Therapeutics Plc (AKTX) Operating income 2016–2025
Akari Therapeutics Plc (AKTX) annual operating income history from SEC filings — each fiscal year as reported.
-$17.3MFY2025 · since FY2016: -$27.2M → -$17.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$17.3M | +20.2% |
| FY2024 | -$21.6M | -28.8% |
| FY2023 | -$16.8M | +27.2% |
| FY2022 | -$23.1M | -34.1% |
| FY2021 | -$17.2M | +4.3% |
| FY2020 | -$18.0M | -6.0% |
| FY2019 | -$17.0M | +18.4% |
| FY2018 | -$20.8M | +45.0% |
| FY2017 | -$37.8M | -38.7% |
| FY2016 | -$27.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More AKTX financial trends
AKTX RevenueAKTX Net incomeAKTX Net marginAKTX Gross profitAKTX Gross marginAKTX Operating marginAKTX Operating cash flowAKTX Free cash flowAKTX Capital expendituresAKTX Return on equityAKTX Stock buybacksAKTX Dividends paidAKTX Total assetsAKTX Total liabilitiesAKTX Shareholders’ equityAKTX overview →